Abetimus Sodium (Riquent) for the Prevention of Nephritic Flares in Patients with Systemic Lupus Erythematosus

This publication has 13 references indexed in Scilit:

• Relationship between anti–double‐stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus
  Arthritis & Rheumatism, 2005
• Abetimus sodium: a new therapy for delaying the time to, and reducing the incidence of, renal flare and/or major systemic lupus erythematosus flares in patients with systemic lupus erythematosus who have a history of renal disease
  Expert Opinion on Investigational Drugs, 2005
• LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus
  Lupus, 2004
• LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double‐blind, placebo‐controlled study
  Arthritis & Rheumatism, 2003
• Antibodies to DNA
  New England Journal of Medicine, 1998
• Pharmacological intervention in antibody mediated disease
  Lupus, 1996
• High-Affinity Anti-DNA Antibody Parallels Clinical Course of Immunoadsorption Therapy for Systemic Lupus Erythematosus.
  Internal Medicine, 1996
• Immunospecific Reduction of Antioligonucleotide Antibody-Forming Cells with a Tetrakis-oligonucleotide Conjugate (LJP 394), a Therapeutic Candidate for the Treatment of Lupus Nephritis
  Journal of Medicinal Chemistry, 1995
• Measurement of increases in anti‐double‐stranded dna antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus
  Arthritis & Rheumatism, 1990
• Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis.
  Journal of Clinical Investigation, 1977